Related Experiment Videos
Stability of BCG vaccines.
Developments in Biological Standardization
|January 1, 1986
Summary
This study shows that freeze-dried Bacillus Calmette-Guérin (BCG) vaccine remains stable in vials at 4°C and 37°C. This stability supports its use in large-scale immunization programs.
Area of Science:
- Vaccinology
- Microbiology
- Pharmaceutical Stability
Background:
- Bacillus Calmette-Guérin (BCG) vaccine is crucial for tuberculosis prevention.
- Current BCG vaccine formulations require specific storage conditions.
- Evaluating vaccine stability in alternative presentations is essential for wider accessibility.
Purpose of the Study:
- To assess the stability of freeze-dried BCG vaccine in amber vials with butyl rubber stoppers.
- To determine stability across different vial sizes (1, 10, 20, 50 doses).
- To evaluate stability at controlled temperatures (4°C and 37°C).
Main Methods:
- Freeze-dried BCG vaccine was packaged in amber vials sealed with grey butyl rubber stoppers.
- Vials of varying dose capacities were stored at 4°C and 37°C.
- Stability was assessed over defined time points (1, 10, 20, 50 days).
Main Results:
- The freeze-dried BCG vaccine demonstrated stability in the tested vial presentation.
- Stability was maintained at both 4°C and 37°C across all vial sizes.
- No significant degradation was observed under the study conditions.
Conclusions:
- The vial presentation of freeze-dried BCG vaccine is a stable product.
- This stable formulation is suitable for use in mass immunization campaigns.
- The findings support the potential for improved BCG vaccine logistics and delivery.